HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
3,4,5- trihydroxy- 1- (4'- phenoxybenzenesulfonyl)piperidine- 2- hydroxy amide
a matrix metalloproteinase and ADAM inhibitor with antipsoriatic activity; structure in first source
Also Known As:
3,4,5-trihydroxy-PBSPHA; CB-12181
Networked:
1
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amines: 4871
Hydroxylamines: 16
Hydroxamic Acids: 239
3,4,5-trihydroxy-1-(4'-phenoxybenzenesulfonyl)piperidine-2-hydroxy amide: 1
Carboxylic Acids: 973
Hydroxy Acids: 94
Hydroxamic Acids: 239
3,4,5-trihydroxy-1-(4'-phenoxybenzenesulfonyl)piperidine-2-hydroxy amide: 1
Sulfur Compounds: 278
Sulfones: 534
3,4,5-trihydroxy-1-(4'-phenoxybenzenesulfonyl)piperidine-2-hydroxy amide: 1
Experts
1.
Chikaraishi, Yuichi
: 1 article (08/2009)
2.
Hara, Hideaki
: 1 article (08/2009)
3.
Shimazawa, Masamitsu
: 1 article (08/2009)
4.
Yokota, Koichi
: 1 article (08/2009)
5.
Yoshino, Koichiro
: 1 article (08/2009)
Related Diseases
1.
Retinal Neovascularization
08/01/2009 - "
Furthermore, in the in vivo angiogenesis model, administration of CB-12181 significantly suppressed retinal neovascularization without any apparent side effects on physiological revascularization to the oxygen-induced obliteration area.
"
08/01/2009 - "
CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo.
"
08/01/2009 - "
To evaluate the anti-angiogenic efficacy of CB-12181 [an azasugar derivative that has inhibitory actions against matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE)], we investigated the suppressing ability on in vitro (tube formation by endothelial cells) and in vivo (retinal neovascularization on murine ischemia-induced proliferative retinopathy) models of angiogenesis.
"
2.
Retinopathy of Prematurity (Retrolental Fibroplasia)
08/01/2009 - "
These results suggest that CB-12181 might be useful in the treatment of various diseases that depend on pathologic angiogenesis, and especially valuable for the treatment of diabetic retinopathy and retinopathy of prematurity.
"
3.
Pathologic Neovascularization
08/01/2009 - "
These results suggest that CB-12181 might be useful in the treatment of various diseases that depend on pathologic angiogenesis, and especially valuable for the treatment of diabetic retinopathy and retinopathy of prematurity.
"
4.
Ischemia
08/01/2009 - "
To evaluate the anti-angiogenic efficacy of CB-12181 [an azasugar derivative that has inhibitory actions against matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE)], we investigated the suppressing ability on in vitro (tube formation by endothelial cells) and in vivo (retinal neovascularization on murine ischemia-induced proliferative retinopathy) models of angiogenesis.
"
5.
Diabetic Retinopathy (Retinopathy, Diabetic)
08/01/2009 - "
These results suggest that CB-12181 might be useful in the treatment of various diseases that depend on pathologic angiogenesis, and especially valuable for the treatment of diabetic retinopathy and retinopathy of prematurity.
"
Related Drugs and Biologics
1.
Matrix Metalloproteinases (MMPs)
2.
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.
ADAM17 Protein
4.
Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.
Oxygen (Dioxygen)